BioSpace News Archive

The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase

QIAGEN N.V. announced the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell responses of the human immune system to the pathogen that causes COVID-19, which could help researchers find out more about immunity levels and disease progression.

Orexo AB, has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialisation of ZUBSOLV® and naloxone ) sublingual tablet.

Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook.

High profile firm WireBuzz boasts relationships with Fortune 500 firms and nation’s top health care companies

Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock SplitPrior to January 26, 2022

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced that it presented two case reports from the ongoing IMR-687 Phase 2a open label extension clinical trial in adult patients with sickle cell disease at the 62nd American Society of Hematology Annual Meeting and Exposition.

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that the U.S. Food and Drug Administration has accepted the filing of a New Drug Application for brincidofovir as a medical countermeasure for smallpox.

OTCQB: PetVivo Holdings, Inc. an emerging biomedical device company operating in the $19B veterinary market announced it will be exhibiting at the American Association of Equine Practitioners Virtual Convention and Trade Show from December 5th to December 8th, 2020 that can be accessed online at https://convention.aaep.org/.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced that it has been nationally recognized as a Great Place to Work-Certified™ Company in 2020.